GMAP-210 (Trip230) Mouse anti-Human, Unlabeled, Clone: 15, BD
Mouse Monoclonal Antibody
Manufacturer: BD Biosciences 611712
Trip230 was identified as a protein that interacts with retinoblastoma protein (Rb) and the thyroid hormone receptor (TR). The structure of Trip230 includes five coiled-coil segments separated by non-helical linkers, N-terminal and C-terminal leucine zipper domains, and multiple phosphorylation sites. Trip230 is ubiquitously expressed and localized to the Golgi. During cell cycle progression, a significant portion of Trip230 translocates to the nucleus. In addition, activation of TR with thyroid hormone (T3) leads to phosphorylation of Trip230, as well as Trip230 translocation from the Golgi to the nucleus. Interestingly, Trip230 has also been identified as a Golgi microtubule-associated protein of 210kDa (GMAP-210). In vitro , GMAP-210 can bind to the minus end of α-tubulin and γ-tubulin via its C-terminal region, while the N-terminal region is involved in Golgi binding. Overexpression of GMAP-210 leads to enlargement of the Golgi apparatus and alterations in the microtubule cytoskeleton. Thus, GMAP-210/Trip230 is thought to function both as a TR coactivator and as a microtubule-binding protein that anchors the Golgi to the microtubule cytoskeleton.
Host Species: Mouse
Species Reactivity [for Features Main]: Human
Immunogen: Human GMAP-210 aa. 159-365
Immunofluorescence, Western Blotting
|Aqueous buffered solution containing BSA, glycerol, and ≤0.09% sodium azide.|
|Store undiluted at -20°C.|
|Human GMAP-210 aa. 159-365|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok